Strikingly, the administration of the YAP1 activator XMU-MP-1 showcased remarkable efficacy, counteracting these multifaceted events, even in the presence of persistent hyperglycemia and hyperlipidemia in diabetic mice. The gene discussed is YAP1; the disease is hyperlipidemia.